P3.18.74 BNT324-01: A Phase 1b/2 Trial of BNT324/DB-1311 (B7H3 ADC) With BNT327 (PD-L1 x VEGF-A bsAb) in Lung Cancer (SCLC or NSCLC)
Year: 2025
Type: article
Source: Journal of Thoracic Oncology
Authors: A. Schoenfeld, A. Spira, A.E. Lisberg, M. Gutierrez, M. Alexander, K. Sankhala, Y. Cheng, C. Escriu, M. Forster, S. Kao, C. Oakman, O. Ates, T. Cil, E. Felip, A. Navarro, O. Juan Vidal, C-H. Yang, R. Dziadziuszko, J. Mazieres, C. Chouaid, A. Vozy, F. Cappuzzo, D. Cortinovis, B. Zhang, R. Shi, Y. Qiu, L. Fang, H. Mu, Q. Kang-Fortner, S. Liang, M. Pinho, T. Reed, J. Furlanetto, S. Helian, A. OBrate, M. Soland, M. Wenger, R. Tibes, Ö. Türeci, U. Sahin, L. Paz-Ares
Institutions: Memorial Sloan Kettering Cancer Center, University of California, Los Angeles, Hackensack University Medical Center, Medical University of South Carolina, Jilin Province Tumor Hospital, Clatterbridge Cancer Centre NHS Foundation Trust, University College Hospital, Chris O’Brien Lifehouse, Sunshine Hospital, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Sağlık Bilimleri Üniversitesi, Vall d'Hebron Hospital Universitari, Hospital Clínic de Barcelona, Hospital Universitari i Politècnic La Fe, National Taiwan University, Gdańsk Medical University, Hôpital Larrey, Hôpital Intercommunal de Créteil, Pitié-Salpêtrière Hospital, Instituto Nazionale Tumori Regina Elena, Duality Biotherapeutics, Inc. (China), BioNTech (United States), BioNTech (Germany), Hospital Universitario 12 De Octubre
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4415520447